An interventional study of Morning Light Therapy in Inflammatory Bowel Disease, sponsored by Icahn School of Medicine at Mount Sinai. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Icahn School of Medicine at Mount Sinai · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Inflammatory Bowel Diseases by Icahn School of Medicine at Mount Sinai — 2 open to participants now, 3 under way, none of them phase 3. Inflammatory Bowel Diseases · Icahn School of Medicine at Mount Sinai.
Among the 11 studies in Inflammatory Bowel Diseases by Icahn School of Medicine at Mount Sinai, this one is the only one that started in 2026, is one of 5 with no phase, and was the 11th registered.
1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.
Browse Inflammatory Bowel Diseases studies →2 of the 11 studies in Inflammatory Bowel Diseases by Icahn School of Medicine at Mount Sinai are open now, in 1 country. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 30 is below the median of 68 across 875 interventional studies indexed under Inflammatory Bowel Diseases.
Median enrollment 110 across the 6 interventional studies, 94 across the 5 observational. Of the 8 that completed or were terminated, 2 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
Icahn School of Medicine at Mount Sinai is the lead sponsor of 776 studies on the registry; 175 are open to participants now.
Of its 125 completed or terminated interventional studies of FDA-regulated products, 83 (66%) have results posted.
1 of the studies in Inflammatory Bowel Diseases by Icahn School of Medicine at Mount Sinai that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07207200Icahn School of Medicine at Mount SinaiImpact of Morning Light Therapy in IBD | 2027-07-01 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Inflammatory Bowel Diseases by Icahn School of Medicine at Mount Sinai, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The pilot study will focus on the effects of morning light therapy (MLT) in adult patients with ulcerative colitis (UC) who have evidence of poor sleep quality and active inflammation. The specific population is at risk for circadian rhythm sleep-wake disorders and has significant potential benefit from circadian realignment, which may lead to improved sleep quality and, ultimately, UC-related inflammatory activity. During an initial one-week lead-in period, participants will obtain baseline circadian-related labs, complete symptom-related surveys, and use a wearable device continuously to obtain baseline sleep-wake data. After the lead-in week, patients will undergo one hour of MLT while wearing wearable devices continuously and completing daily symptom surveys. At the end of four weeks of MLT, patients will obtain post-intervention circadian and inflammatory assessments in addition to completing the same symptom-related surveys.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients with ulcerative colitis (UC)
Device: Morning Light Therapy
One hour of morning light therapy each day for four weeks
C-reactive protein (CRP) level
C-reactive protein (CRP) is produced by the liver. The CRP test is a general test to check for inflammation in the body.
Time frame: week 4
Fecal Calprotectin (FCP)
The fecal calprotectin is a stool test which measures intestinal inflammation.
Time frame: week 4
Patient-Reported Outcomes Measurement Information System (PROMIS 10)
A series of person-centered measures that evaluate and monitor physical, mental, and social health in adults.
Time frame: week 4
Change in Microbiome composition
Microbiome assessment
Time frame: week 4
Change in Morning urine melatonin level
Urine samples at the beginning and end of the study
Time frame: week 4
Plan to share: No — There is no IRB approval to share individual patient data
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Jul 2027, 12 months after the start.
Of 285 non-industry interventional studies with no phase under Inflammatory Bowel Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 12 months is below that.
Counting every sponsor, half of 299 studies reached it within 26 months; a quarter within 14 and three quarters within 50.
Start moved once since we started tracking on Sep 25, 2026: Mar 2026 → Jul 2026, on Oct 9, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Icahn School of Medicine at Mount Sinai →